Recent Transactions

01-Apr-13
$NA
United States flag
Target: 

Morgans Hotel Group

Advised the Special Transaction Committee of the Board of Morgans Hotel Group on the transfer of its ownership interests in Delano South Beach and The Light Group to The Yucaipa Companies in exchange for the cancellation of certain securities held by Yucaipa (debt, preferred stock and warrants) together with a $100 million rights offering backstopped by Yucaipa

26-Nov-12
$16 billion
United States flag
Target: 

Archstone Enterprise LP

United States flag
Acquiror: 
AvalonBay Communities & Equity Residential

Advised AvalonBay on its joint acquisition with Equity Residential of the assets and liabilities of Archstone Enterprise LP, an owner of high-quality apartment communities in major markets in the United States, from Lehman Brothers Holdings

20-Aug-12
$7.3 billion
United States flag
Target: 

Coventry Health Care Inc.

United States flag
Acquiror: 
Aetna

Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna

16-May-12
$1.5 billion
United States flag
Target: 

Peninsula Gaming, LLC

United States flag
Acquiror: 
Boyd Gaming Corporation

Advised Boyd Gaming Corporation, a leading gaming operator in Nevada, the Midwest and South, on the acquisition of Peninsula Gaming, a casino operator of five properties in Kansas, Iowa and Louisiana

26-Mar-12
$513 million
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

United States flag
Acquiror: 
Bausch + Lomb, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

07-Nov-11
$398 million
United States flag
Target: 

American Dental Partners, Inc.

United States flag
Acquiror: 
JLL Partners

Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm

26-Oct-11
$2.2 billion
U.S.A., Japan flags
Target: 

PGM Holdings K.K. (majority owned by Lone Star Funds)

Japan flag
Acquiror: 
Heiwa Corporation

Advised Heiwa Corporation, a leading provider of pachinko amusement machines, on the tender offer to acquire 80.5% of PGM Holdings K.K., one of the largest golf club owners and operators in Japan, including 64.2% Lone Star Funds’ holding

30-Jun-11
$609 million
Japan flag
Target: 

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

United States flag
Acquiror: 
Royalty Pharma

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

30-Jun-11
$1.7 billion
United Kingdom flag
Target: 

Minerva plc

United Kingdom flag
Acquiror: 
Jupiter Properties (owned by AREA Property Partners and Delancey Real Estate Asset Mgmt)

Advised Minerva plc, a property investment and development company, on a recommended offer from a consortium consisting of AREA Property Partners and Delancey Real Estate Asset Management

16-Jun-11
$288 million
United States flag
Target: 

Imperial Palace Casino Resort and Spa

United States flag
Acquiror: 
Boyd Gaming Corporation

Advised Boyd Gaming Corporation, a leading gaming operator in Nevada, the Midwest and South, on the acquisition of Imperial Palace Casino Resort and Spa in Biloxi, Mississippi

26-May-11
$192 million
Australia flag
Target: 

Centrebet International Limited

United Kingdom flag
Acquiror: 
Sportingbet plc

Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

13-Dec-10
$256 million
United Kingdom flag
Target: 

Maxinutrition Group Holdings Limited

United Kingdom flag
Acquiror: 
GlaxoSmithKline Plc

Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity

07-Dec-10
$500 million
United States flag
Target: 

Medicity, Inc.

United States flag
Acquiror: 
Aetna Inc.

Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

23-Sep-10
$394 million
Australia flag
Target: 

Aevum Ltd.

Australia flag
Acquiror: 
Stockland Corp. Ltd

Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group

21-Sep-10
$234 million
Israel flag
Target: 

Taro Pharmaceutical Industries

India flag
Acquiror: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

12-Jul-10
$NA
United States flag
Target: 

Breast Care Business of Ethicon-Endo Surgery

United States flag
Acquiror: 
Devicor Medical Products, Inc. (a GTCR portfolio company)

Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery

05-Apr-10
$225 million
United States flag
Target: 

Medegen, Inc

United States flag
Acquiror: 
CareFusion Corporation

Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company

10-Mar-10
$576 million
United Kingdom flag
Target: 

Camelot Group plc

Canada flag
Acquiror: 
Ontario Teachers’ Pensions Plan

Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan

23-Feb-10
$NA
United States flag
Target: 

Heartscape Technologies, Inc.

United States flag
Acquiror: 
Roper Industries, Inc.

Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company

08-Jan-10
$134 million
United Kingdom flag
Target: 

Minerva plc

British Virgin Islands flag
Acquiror: 
KiFin Limited

Advised Minerva plc, a UK real estate development company, on its successful defence following an unsolicited offer from KiFin Limited, a company that makes investments for the benefit of Mr Nathan Kirsh

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

Pages

show all